Analysts expect Idera Pharmaceuticals Inc (NASDAQ:IDRA) to post $130,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Idera Pharmaceuticals’ earnings, with estimates ranging from $100,000.00 to $150,000.00. Idera Pharmaceuticals reported sales of $260,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 50%. The firm is expected to issue its next quarterly earnings report on Wednesday, May 8th.

On average, analysts expect that Idera Pharmaceuticals will report full year sales of $490,000.00 for the current financial year, with estimates ranging from $400,000.00 to $580,000.00. For the next year, analysts forecast that the business will post sales of $6.79 million, with estimates ranging from $420,000.00 to $13.15 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.12 million. Idera Pharmaceuticals had a negative return on equity of 75.10% and a negative net margin of 9,045.47%.

A number of research firms recently weighed in on IDRA. Zacks Investment Research cut Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, February 6th. ValuEngine upgraded Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Wedbush set a $7.00 target price on Idera Pharmaceuticals and gave the company an “outperform” rating in a report on Thursday, March 7th. Finally, HC Wainwright lowered their target price on Idera Pharmaceuticals to $14.00 and set a “buy” rating on the stock in a report on Friday, March 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.71.

A number of large investors have recently made changes to their positions in IDRA. Virtu Financial LLC acquired a new stake in Idera Pharmaceuticals during the 4th quarter valued at $33,000. Jane Street Group LLC acquired a new stake in shares of Idera Pharmaceuticals during the fourth quarter worth $39,000. SG Americas Securities LLC acquired a new stake in shares of Idera Pharmaceuticals during the fourth quarter worth $41,000. Squarepoint Ops LLC boosted its holdings in shares of Idera Pharmaceuticals by 45.5% during the fourth quarter. Squarepoint Ops LLC now owns 18,900 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 5,910 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Idera Pharmaceuticals during the fourth quarter worth $61,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Shares of IDRA traded up $0.20 on Tuesday, reaching $2.57. The stock had a trading volume of 222,948 shares, compared to its average volume of 328,508. The stock has a market cap of $70.98 million, a P/E ratio of -1.13 and a beta of 2.55. Idera Pharmaceuticals has a twelve month low of $2.25 and a twelve month high of $17.12.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Further Reading: Hedge Funds

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.